Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | yes | yes: 10 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 6 |
NetGPI | no | yes: 0, no: 6 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005874 | microtubule | 6 | 7 |
GO:0099080 | supramolecular complex | 2 | 7 |
GO:0099081 | supramolecular polymer | 3 | 7 |
GO:0099512 | supramolecular fiber | 4 | 7 |
GO:0099513 | polymeric cytoskeletal fiber | 5 | 7 |
GO:0110165 | cellular anatomical entity | 1 | 7 |
Related structures:
AlphaFold database: A4HLD6
Term | Name | Level | Count |
---|---|---|---|
GO:0007017 | microtubule-based process | 2 | 7 |
GO:0009987 | cellular process | 1 | 7 |
Term | Name | Level | Count |
---|---|---|---|
GO:0000166 | nucleotide binding | 3 | 7 |
GO:0003824 | catalytic activity | 1 | 7 |
GO:0003924 | GTPase activity | 7 | 7 |
GO:0005198 | structural molecule activity | 1 | 7 |
GO:0005200 | structural constituent of cytoskeleton | 2 | 7 |
GO:0005488 | binding | 1 | 7 |
GO:0005525 | GTP binding | 5 | 7 |
GO:0016462 | pyrophosphatase activity | 5 | 7 |
GO:0016787 | hydrolase activity | 2 | 7 |
GO:0016817 | hydrolase activity, acting on acid anhydrides | 3 | 7 |
GO:0016818 | hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides | 4 | 7 |
GO:0017076 | purine nucleotide binding | 4 | 7 |
GO:0017111 | ribonucleoside triphosphate phosphatase activity | 6 | 7 |
GO:0019001 | guanyl nucleotide binding | 5 | 7 |
GO:0032553 | ribonucleotide binding | 3 | 7 |
GO:0032555 | purine ribonucleotide binding | 4 | 7 |
GO:0032561 | guanyl ribonucleotide binding | 5 | 7 |
GO:0035639 | purine ribonucleoside triphosphate binding | 4 | 7 |
GO:0036094 | small molecule binding | 2 | 7 |
GO:0043167 | ion binding | 2 | 7 |
GO:0043168 | anion binding | 3 | 7 |
GO:0097159 | organic cyclic compound binding | 2 | 7 |
GO:0097367 | carbohydrate derivative binding | 2 | 7 |
GO:1901265 | nucleoside phosphate binding | 3 | 7 |
GO:1901363 | heterocyclic compound binding | 2 | 7 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_NRD_NRD_1 | 113 | 115 | PF00675 | 0.336 |
CLV_NRD_NRD_1 | 124 | 126 | PF00675 | 0.566 |
CLV_PCSK_KEX2_1 | 113 | 115 | PF00082 | 0.326 |
CLV_PCSK_KEX2_1 | 124 | 126 | PF00082 | 0.608 |
CLV_PCSK_SKI1_1 | 125 | 129 | PF00082 | 0.609 |
CLV_PCSK_SKI1_1 | 43 | 47 | PF00082 | 0.288 |
CLV_PCSK_SKI1_1 | 93 | 97 | PF00082 | 0.326 |
DOC_MAPK_gen_1 | 93 | 101 | PF00069 | 0.509 |
DOC_MAPK_MEF2A_6 | 93 | 101 | PF00069 | 0.509 |
DOC_USP7_MATH_1 | 6 | 10 | PF00917 | 0.495 |
LIG_14-3-3_CanoR_1 | 16 | 21 | PF00244 | 0.495 |
LIG_14-3-3_CanoR_1 | 43 | 51 | PF00244 | 0.509 |
LIG_14-3-3_CanoR_1 | 52 | 60 | PF00244 | 0.508 |
LIG_Actin_WH2_2 | 80 | 98 | PF00022 | 0.526 |
LIG_BRCT_BRCA1_1 | 47 | 51 | PF00533 | 0.509 |
LIG_BRCT_BRCA1_1 | 71 | 75 | PF00533 | 0.526 |
LIG_BRCT_BRCA1_1 | 97 | 101 | PF00533 | 0.565 |
LIG_CAP-Gly_1 | 169 | 177 | PF01302 | 0.726 |
LIG_FHA_1 | 55 | 61 | PF00498 | 0.518 |
LIG_FHA_2 | 141 | 147 | PF00498 | 0.625 |
LIG_FHA_2 | 161 | 167 | PF00498 | 0.632 |
LIG_LIR_Nem_3 | 110 | 115 | PF02991 | 0.526 |
LIG_LIR_Nem_3 | 12 | 18 | PF02991 | 0.495 |
LIG_LIR_Nem_3 | 154 | 159 | PF02991 | 0.599 |
LIG_MLH1_MIPbox_1 | 71 | 75 | PF16413 | 0.526 |
LIG_PCNA_yPIPBox_3 | 105 | 114 | PF02747 | 0.526 |
LIG_Pex14_2 | 119 | 123 | PF04695 | 0.586 |
LIG_SH2_CRK | 15 | 19 | PF00017 | 0.495 |
LIG_SH2_SRC | 159 | 162 | PF00017 | 0.625 |
LIG_SH2_STAT5 | 132 | 135 | PF00017 | 0.595 |
LIG_SH2_STAT5 | 44 | 47 | PF00017 | 0.493 |
LIG_SH2_STAT5 | 74 | 77 | PF00017 | 0.511 |
LIG_TRAF2_1 | 163 | 166 | PF00917 | 0.652 |
MOD_CK1_1 | 9 | 15 | PF00069 | 0.495 |
MOD_CK2_1 | 140 | 146 | PF00069 | 0.628 |
MOD_CK2_1 | 16 | 22 | PF00069 | 0.495 |
MOD_CK2_1 | 160 | 166 | PF00069 | 0.624 |
MOD_CK2_1 | 53 | 59 | PF00069 | 0.509 |
MOD_GlcNHglycan | 47 | 50 | PF01048 | 0.309 |
MOD_GSK3_1 | 140 | 147 | PF00069 | 0.600 |
MOD_GSK3_1 | 5 | 12 | PF00069 | 0.495 |
MOD_LATS_1 | 41 | 47 | PF00433 | 0.509 |
MOD_N-GLC_1 | 103 | 108 | PF02516 | 0.326 |
MOD_N-GLC_1 | 70 | 75 | PF02516 | 0.326 |
MOD_N-GLC_2 | 105 | 107 | PF02516 | 0.326 |
MOD_NEK2_1 | 45 | 50 | PF00069 | 0.509 |
MOD_NEK2_1 | 95 | 100 | PF00069 | 0.509 |
MOD_PIKK_1 | 21 | 27 | PF00454 | 0.428 |
MOD_PIKK_1 | 9 | 15 | PF00454 | 0.495 |
MOD_PK_1 | 16 | 22 | PF00069 | 0.495 |
MOD_PKA_2 | 53 | 59 | PF00069 | 0.509 |
MOD_PKA_2 | 9 | 15 | PF00069 | 0.495 |
MOD_PKB_1 | 52 | 60 | PF00069 | 0.509 |
MOD_Plk_1 | 103 | 109 | PF00069 | 0.526 |
MOD_Plk_1 | 160 | 166 | PF00069 | 0.610 |
MOD_Plk_1 | 70 | 76 | PF00069 | 0.526 |
MOD_Plk_4 | 70 | 76 | PF00069 | 0.526 |
MOD_Plk_4 | 97 | 103 | PF00069 | 0.509 |
TRG_ENDOCYTIC_2 | 15 | 18 | PF00928 | 0.495 |
TRG_ER_diArg_1 | 112 | 114 | PF00400 | 0.545 |
TRG_ER_diArg_1 | 123 | 125 | PF00400 | 0.562 |
TRG_ER_diArg_1 | 51 | 54 | PF00400 | 0.509 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0S4IVQ1 | Bodo saltans | 31% | 96% |
A0A0S4J902 | Bodo saltans | 98% | 100% |
A0A0S4KMQ2 | Bodo saltans | 34% | 92% |
A0A1X0NW87 | Trypanosomatidae | 35% | 100% |
A0A3S7X6J0 | Leishmania donovani | 100% | 73% |
A0A3S7X6K6 | Leishmania donovani | 100% | 100% |
A4HHS1 | Leishmania braziliensis | 32% | 68% |
A4HLD1 | Leishmania braziliensis | 100% | 100% |
C9ZIG1 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 32% | 93% |
E8NHQ9 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 33% | 100% |
P02553 | Lytechinus pictus | 33% | 100% |
P02556 | Lytechinus pictus | 85% | 100% |
P24635 | Octopus vulgaris | 33% | 74% |
P33632 | Anemia phyllitidis | 83% | 74% |
Q07972 | Pneumocystis carinii | 33% | 83% |
V5AN49 | Trypanosoma cruzi | 97% | 100% |